News Sentiment

ABUS sentiment intelligence

Arbutus Biopharma Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.56 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-5.0% over one week, +0.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -5.0% Price reacting lower
Trend fit Trend active 0.2% over four weeks
Fair value 32.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 9
GuruFocus 5
TradingKey 5
simplywall.st 4
Seeking Alpha 3
Investing.com 3
TradingView 3

Event Lens

What the news is about

Classified themes
Earnings 25
Market update 24
Regulatory and legal 4
Capital return 2
Balance sheet 1
Analyst action 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
GuruFocus Direct company coverage

Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT Over Patent Dispute

Arbutus Biopharma (ABUS) and Genevant Sciences have filed three international lawsuits against Pfizer and BioNTech, alleging patent infringement related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a similar U.S. dispute and a $178 million settle

Tone
Negative 39/100
Event
Regulatory and legal
Published
16 Jul 2026 14:42
Source
GuruFocus
GuruFocus Direct company coverage

Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNTech Over Patent Dispute

Arbutus Biopharma (ABUS) and Genevant Sciences have initiated three international lawsuits against Pfizer and BioNTech, alleging patent infringements related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a prior U.S. dispute and a $178 million set

Tone
Neutral 50/100
Event
Regulatory and legal
Published
16 Jul 2026 13:18
Source
GuruFocus
GuruFocus Direct company coverage

Arbutus (ABUS) Secures $178 Million Settlement with Moderna

Arbutus Biopharma Corp (ABUS) has secured a $178 million settlement with Moderna to resolve patent infringement disputes related to Moderna’s COVID-19 vaccines. This payment will bolster Arbutus's cash reserves and allow it to focus on its core business of developing therapeutics

Tone
Positive 72/100
Event
Balance sheet
Published
16 Jul 2026 12:52
Source
GuruFocus
Quiver Quantitative Direct company coverage

Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return

Arbutus Biopharma and its licensee Genevant have filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their lipid nanoparticle technology, seeking monetary damages and injunctions. This follows Arbutus receiving approximately $178 mill

Tone
Positive 65/100
Event
Regulatory and legal
Published
16 Jul 2026 11:42
Source
Quiver Quantitative
Stock Titan Direct company coverage

Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback

Arbutus Biopharma received approximately $178 million from a settlement with Moderna regarding mRNA patent disputes and may receive up to an additional $1.3 billion. The company also announced plans to return up to $230 million to shareholders through common share repurchases, co

Tone
Positive 76/100
Event
Capital return
Published
16 Jul 2026 11:41
Source
Stock Titan
Stock Titan Direct company coverage

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma, and its licensee Genevant, have initiated three international lawsuits against Pfizer and BioNTech for patent infringement related to their innovative LNP technology used in COVID-19 vaccines. Concurrently, Arbutus announced the receipt of approximately $178 mi

Tone
Neutral 50/100
Event
Regulatory and legal
Published
16 Jul 2026 11:41
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Arbutus Biopharma stock hits 52-week high at 5.34 USD By Investing.com

Arbutus Biopharma's stock reached a 52-week high of $5.34, reflecting strong investor confidence with a 56% return over the past year and a market capitalization of $1.05 billion. The company holds an "EXCELLENT" financial health score and its drug imdusiran recently received Fas

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 17:15
Source
Investing.com Nigeria
Market source Direct company coverage

Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks

Arbutus Biopharma (ABUS) has been added to the Russell 2000 Growth Defensive and Russell 2000 Defensive Indexes, while simultaneously being removed from several value-oriented Russell indexes. This reclassification may influence the types of index-linked funds and mandates that h

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 15:11
Source
Market source
Investing.com Direct company coverage

Arbutus Biopharma stock hits 52-week high at 5.34 USD

Arbutus Biopharma's stock has reached a new 52-week high of $5.34, reflecting strong investor confidence and a 56% return over the past year. The company, with a market capitalization of $1.05 billion, has an "EXCELLENT" financial health score and an impressive gross profit margi

Tone
Positive 73/100
Event
Earnings
Published
09 Jul 2026 10:30
Source
Investing.com
Finviz Direct company coverage

ABUS - Arbutus Biopharma Corp Options

This article provides a detailed overview of Arbutus Biopharma Corp (ABUS) stock options and key financial metrics. It includes recent stock performance, company financials like market cap, income, sales, and various ratios, along with insider and institutional ownership data. Th

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 09:41
Source
Finviz
TradingKey Direct company coverage

Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Arbutus Biopharma Corp (ABUS), noting its current valuation score of 8.58, which ranks it 115 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of 5.38, which is slightly below

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 18:09
Source
TradingKey
TradingKey Direct company coverage

Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

The article provides a technical analysis of Arbutus Biopharma Corp (ABUS), focusing on its support and resistance levels, various technical indicators, and moving averages. It highlights that ABUS currently has a price momentum score of 8.98 and is trading between a resistance l

Tone
Positive 66/100
Event
Market update
Published
18 Jun 2026 04:09
Source
TradingKey
TradingKey Direct company coverage

Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Arbutus Biopharma Corp (ABUS) has an earnings forecast score of 8.67, ranking well within the Biotechnology & Medical Research industry. Analysts provide an average price target of $5.00 with a Buy rating. The company's expected revenue for the next quarter is $450.00K, and the E

Tone
Positive 62/100
Event
Earnings
Published
17 Jun 2026 23:09
Source
TradingKey
TradingKey Direct company coverage

Arbutus Biopharma Corp (ABUS) Institutional Confidence

The article details the institutional confidence score for Arbutus Biopharma Corp (ABUS), which currently stands at 5.00, ranking it 133rd out of 388 in its industry. Institutional shareholding has increased to 65.56%, a 3.63% quarter-over-quarter rise. The largest institutional

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 02:40
Source
TradingKey
TradingKey Direct company coverage

Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Arbutus Biopharma Corp (ABUS), identifying its major shareholders, their proportional holdings, and the types of shareholders. It also provides institutional shareholding data over various quarters and lists related ETFs that hold

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 02:39
Source
TradingKey
Market source Direct company coverage

Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results

Arbutus Biopharma Corporation (ABUS) announced significant Q1 2026 results, reporting $179.1 million in revenue, a substantial increase from $1.8 million a year prior, largely due to a litigation settlement with Moderna. The company swung from a $24.5 million loss to a net income

Tone
Positive 71/100
Event
Earnings
Published
13 Jun 2026 18:06
Source
Market source
Simply Wall Street Direct company coverage

Arbutus Biopharma (Nasdaq:ABUS) - Stock Analysis

Arbutus Biopharma (ABUS) is a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases, particularly chronic Hepatitis B virus (HBV). The company became profitable this year, exceeding analyst expectations for its first quarter 2026 earning

Tone
Positive 63/100
Event
Earnings
Published
12 Jun 2026 01:09
Source
Simply Wall Street
Stock Titan Direct company coverage

Arbutus Biopharma (ABUS) director awarded fully vested options on 78,800 shares

Arbutus Biopharma director Roger Sawhney was granted fully vested stock options for 78,800 common shares at an exercise price of $4.24 per share, matching the closing price on the grant date of June 8, 2026. This equity compensation award is immediately exercisable and expires on

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 01:38
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Arbutus Biopharma Corp Insider Trading Activity

Arbutus Biopharma director Robert A. Beardsley was granted 78,800 fully vested stock options with an exercise price of $4.24 per share, expiring on June 8, 2036. This transaction is categorized as a compensation-related award, not an open-market purchase or sale. The options are

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 19:40
Source
Stock Titan
Finviz Direct company coverage

ABUS - Arbutus Biopharma Corp Stock Price and Quote

This page provides a comprehensive overview of Arbutus Biopharma Corp (ABUS) stock, including its latest trading data, financial metrics, analyst ratings, and recent news headlines. Key financial figures like market cap, income, sales, and employee count are listed, alongside per

Tone
Positive 64/100
Event
Analyst action
Published
29 May 2026 20:09
Source
Finviz
Stock Titan Direct company coverage

Shareholders at Arbutus Biopharma (NASDAQ: ABUS) approve 2026 share plan and auditor

Arbutus Biopharma Corporation's shareholders approved the 2026 Omnibus Share and Incentive Plan, authorizing 16,300,000 common shares for equity-based compensation. They also re-elected all director nominees, approved executive compensation on a non-binding advisory basis, and ra

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake

Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi have reported a beneficial ownership of 18,557,543 common shares, representing a 9.4% stake in Arbutus Biopharma Corporation (NASDAQ: ABUS). This stake is held through two funds: Two Seas Global (Master) Fund LP and Tw

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 May 2026 00:35
Source
Stock Titan